A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC	TNBC	Enrolling by invitation	Phase 2	2026-01-29		NCT07376629

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Huabo Biopharm Co., Ltd.	3

23 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Affiliated Hospital of Jining Medical University	Jining	China	12
Anhui Provincial Hospital	Hefei	China	34
Anyang Cancer Hospital	Anyang	China	4
Fudan University Shanghai Cancer Center	Shanghai	China	128
Fujian Cancer Hospital	Fujian	China	5
Guangdong Provincial People's Hospital	Guangdong	China	5
Harbin Medical University Cancer Hospital	Harbin	China	35
Jiangsu Province Hospital	Nanjing	China	39
Liaoning Cancer Hospital	Shengyang	China	2
Linyi Cancer Hospital	Linyi	China	19
Shandong Cancer Hospital	Shandong	China	3
Shanxi Cancer hospital	Shanxi	China	2
Sichuan Cancer Hospital	Chengdu	China	21
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine	Hangzhou	China	4
Sun Yat-Sen University Cancer Center	Guangzhou	China	66
The First Affiliated Hospital of Xiamen University	Xiamen	China	40
The First Hospital of Jilin University	Jilin City	China	8
The Second Affiliated Hospital of Soochow University	Suzhou	China	13
The Second Affiliated Hospital of Xi'an Jiaotong University	Xi'an	China	22
Tianjin Cancer Hospital	Tianjing	China	1
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	China	37
Xiangya Hospital central south university	Changsha	China	12
Xuzhou Central Hospital	Xuzhou	China	16

Clinical trials